Implantable Drug Delivery Patent Landscape 2026
The standalone implantable drug delivery space is led by Medtronic, which holds a commanding position among the top filers, with the field showing a multi-year activity base that has eased from its 2020 peak. Activity is moderately concentrated among a mix of device makers, pharma companies, and academic institutions, with fluid-delivery and medicinal-formulation branches dominating the technology mix.
Medtronic leads a moderately concentrated field with a diverse second tier
Medtronic is the clear top-ranked filer, followed by Massachusetts Institute of Technology and Tolmar Therapeutics at equal rank, with Microchips Inc and Janssen Biotech rounding out the top five. The top five filers together account for 30% of the combined total across the hundred largest filers.
The tier gap between Medtronic and the rest is substantial, but the second tier includes a heterogeneous mix of academic institutions, specialty pharma firms, and device start-ups, indicating that no single strategic playbook dominates beyond the leader.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Medtronic Inc | 94 | |
| 2 | Massachusetts Institute of Technology | 43 | |
| 3 | Tolmar Therapeutics Inc | 43 | |
| 4 | Microchips Inc | 32 | |
| 5 | Janssen Biotech Inc | 31 | |
| 6 | QLT USA Inc | 26 | |
| 7 | MASSACHUSETTS EYE & EAR INFARY | 23 | |
| 8 | Durect Corporation | 23 | |
| 9 | The Charles Stark Draper Laboratory Inc | 22 | |
| 10 | CODMAN & SHURTLEFF INC | 22 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Atrix Laboratories Inc | 18 | |
| 12 | Sten Olof Elfver | 16 | |
| 13 | Microchips Biotech Inc | 15 | |
| 14 | Oak Crest Institute of Science | 14 | |
| 15 | AcuityBio Corporation | 14 | |
| 16 | Braeburn Pharmaceuticals Inc | 14 | |
| 17 | Infusyn Therapeutics LLC | 13 | |
| 18 | Implantica Patent Ltd | 12 | |
| 19 | MedicalTree Patent Ltd | 12 | |
| 20 | Dare MB Inc | 11 |
Medtronic’s lead reflects long-standing investment in implantable pump and catheter systems; the presence of MIT and Charles Stark Draper Laboratory signals that academic innovation pipelines remain active and could feed into commercial challengers.
Patent records published in the most recent 18–24 months are subject to publication lag and likely under-represent actual filing activity; conclusions about very recent years should be treated as provisional. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Filing volume peaked in 2020 and has eased; device-fluid and formulation branches dominate
The annual filing trend and technology composition charts together show where activity has been concentrated over time and which IPC branches define the core of the field versus its periphery.
Annual filing trend
Annual filings peaked at 31 records in 2020 and have since eased. The 2024 and 2025 figures appear low but are affected by publication lag and should not be read as continued decline; the multi-year window still captures a meaningful body of activity.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61M (devices for body fluids) and A61K (medicinal preparations) together account for the largest share of patent records by a wide margin, reflecting the dual device-and-formulation character of the field. A61L, A61P, and A61F form a secondary tier, while digital, polymer, and wireless branches each hold a small but technically relevant share.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Implantable drug delivery devices for genitourinar…
Implantable drug delivery devices are provided to have a deployment shape for implantation in the body and a retention shape for retention in the body. The device may have one or more elongated drug reservoirs containing a drug, and the drug reservoir may be formed from a deformable material. In one case, a first filament is attached to the first end of the… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Low-permeability, laser-activated drug delivery de… | 1,357 |
| 2 | Implantable drug delivery catheter system with cap… | 950 |
| 3 | Biodegradable, implantable drug delivery depots, a… | 938 |
| 4 | Implantable drug delivery system | 617 |
| 5 | Refillable implantable drug delivery pump | 510 |
| 6 | Liquid delivery compositions | 491 |
| 7 | Controlled release delivery compositions | 476 |
| 8 | Biodegradable, implantable drug delivery device, a… | 470 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the patent structure means for R&D investment decisions
Four structural reads — maturity, concentration, collaboration, and geography — together frame the strategic context for teams evaluating entry or expansion in this space.
Field is in a post-peak, declining phase
The lifecycle stage is classified as Decline, with annual filings easing back from the 2020 peak. Teams should expect a narrowing of broad platform patents and increasing specificity in new filings. R&D investment is more defensible in differentiated sub-niches than in the well-covered core device-pump space.
Lifecycle: DeclineOne dominant leader, fragmented second tier
Medtronic’s lead in patent records is large relative to any single challenger, but the second tier spans academic labs, specialty pharma, and device start-ups without a clear second-place consolidator. This fragmentation suggests that licensing, acquisition, or academic partnership could be effective entry strategies for a new commercial player.
Herfindahl: moderateMIT–General Hospital and Milux–MedicalTree are the most active co-filing pairs
The most active co-applicant pair is Massachusetts Institute of Technology with The General Hospital Corporation (8 joint filings), followed by MIT with Children’s Medical Center Corporation (5 filings). Milux Holding co-files with both MedicalTree Patent Ltd (4 filings) and Implantica Patent Ltd (3 filings), suggesting a patent-holding cluster strategy. These pairs represent the ecosystem’s most active collaborative nodes.
Co-filing: academic + holdingUS-centric protection with selective EPO and PCT coverage
The United States is the dominant filing jurisdiction, followed by Europe (EPO) and WIPO (PCT). Australia and Canada form a secondary English-language coverage tier. China and India each have limited representation, suggesting that competitors could find relatively open ground in Asian markets for overlapping technical claims.
Lead office: USGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Massachusetts Institute of Technology | The General Hospital Corporation | 8 |
| Massachusetts Institute of Technology | Children’s Medical Center Corporation | 5 |
| Milux Holding | MedicalTree Patent Ltd | 4 |
| Milux Holding | Implantica Patent Ltd | 3 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Medtronic anchors the field; Taris Biomedical is the momentum-tracked challenger
The two applicants with tracked momentum data represent very different trajectories: an established device leader holding a large portfolio and a specialist challenger showing a recent decline from an earlier activity spike.
Medtronic
Medtronic is the top-ranked filer with 94 patent records, concentrated in A61M5 (infusion devices), A61K9 (drug formulations), and A61M31 (implantable fluid delivery). Its breadth across both device hardware and formulation IP creates a wide defensive moat. Momentum data for Medtronic is not separately tracked in the evidence, but its scale alone sustains leadership.
patent records: 94Taris Biomedical
Taris Biomedical (ranked outside the top five by record count but tracked for momentum) shows a recent trend of ▼ –67%, indicating a sharp pullback in recent filings from an earlier higher base. Its technology focus is concentrated in A61M31, A61K9, and A61K31 — device-and-formulation combinations aligned with intravesical and localized delivery systems. The decline may reflect portfolio consolidation or commercial-stage transition rather than exit.
trend: ▼ -67%| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Massachusetts Institute of Technology | 2 | ▲ new entrant |
Under-served branches adjacent to the core device and formulation space
Several IPC branches appear in the corpus at relatively low shares, sitting adjacent to the dominant A61M and A61K core. These observations reflect relative sparsity and are presented as areas to investigate further, not as validated commercial opportunities.
A61N · Electrotherapy & radiation therapy
With 43 patent records and a 2% share of the corpus, A61N is the sparsest of the five adjacent branches identified. Implantable devices that combine controlled drug release with electrical stimulation — for instance in neuromodulation or cardiac applications — sit at the intersection of A61M and A61N but are underrepresented relative to the device-only neuromodulation field. Teams with expertise in closed-loop stimulation hardware may find fewer blocking patents here than in the core fluid-delivery space. Entry would require demonstrating added clinical value over standalone stimulators.
Search this in Eureka →A61B · Diagnosis & surgery
A61B accounts for 36 patent records at a 2% share, the lowest-density branch among those with plausible technical adjacency. Implantable systems that integrate sensing or diagnostic capability with drug release — enabling closed-loop, biomarker-triggered delivery — fall into this branch but are sparsely covered. The technical pathway is realistic given existing biosensor miniaturization trends, and the sparse coverage suggests room for differentiated claims. Commercial entry would depend on demonstrating reliable in-vivo sensing paired with controlled release.
Search this in Eureka →How leading applicants differ by technology branch emphasis
Route coverage across the main technology branches in the current evidence set.
| Player | A61K 9 · Medicinal preparations | A61M 5 · Devices for body fluids | A61M 31 · Devices for body fluids | A61K 47 · Medicinal preparations | A61K 31 · Medicinal preparations |
|---|---|---|---|---|---|
| Medtronic | Moderate · 32 | Strong · 90 | Moderate · 31 | Absent | Absent |
| Atrix Laboratories | Strong · 42 | Absent | Absent | Strong · 42 | Absent |
| Microchips Inc | Strong · 38 | Strong · 30 | Emerging · 6 | Absent | Absent |
| Massachusetts Institute of Technology | Strong · 19 | Absent | Strong · 32 | Moderate · 8 | Moderate · 11 |
| QLT USA Inc | Strong · 29 | Absent | Absent | Strong · 27 | Absent |
| Codman & Shurtleff Inc | Strong · 22 | Strong · 23 | Absent | Absent | Absent |
Frequently asked questions
The corpus covers 142 patent families in the standalone implantable drug delivery topic. This is a focused corpus and should be interpreted alongside the broader implantable drug delivery field.
Medtronic is the top-ranked applicant with 94 patent records, a substantial lead over the next-ranked filers Massachusetts Institute of Technology and Tolmar Therapeutics, each with 43 patent records.
The field is classified as Decline, with annual filings having eased back from a peak of 31 records in 2020. The most recent years are subject to publication lag, so the very latest figures may undercount actual activity.
The United States leads all jurisdictions, followed by Europe (EPO) and WIPO (PCT). Australia and Canada form a secondary coverage tier. China and India each have relatively limited coverage in this corpus.
The most active co-applicant pair is Massachusetts Institute of Technology with The General Hospital Corporation, with 8 joint filings. MIT also co-files with Children’s Medical Center Corporation (5 filings). Milux Holding co-files with MedicalTree Patent Ltd (4 filings) and Implantica Patent Ltd (3 filings).
The sparsest adjacent branches identified are A61N (electrotherapy and radiation therapy) and A61B (diagnosis and surgery), each at a 2% share of patent records. Both represent plausible technical adjacencies for combined sensing-and-delivery or stimulation-and-delivery systems but have substantially fewer filings than the core A61M and A61K branches.
Ready to map your own implantable drug delivery landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.